Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis By Ogkologos - June 18, 2026 86 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SENTRY study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Study Says Educational Materials for Chemo Often Require Higher Reading Level... September 25, 2019 Can Eating Soy Cause Breast Cancer? October 19, 2021 The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... April 16, 2021 How to Spend Time with Friends and Family Now that COVID... August 13, 2020 Load more HOT NEWS First Global Estimates of Cervical Cancer Attributable to HIV Becoming My Own Advocate While Living With a Rare Cancer: A... Teacher on Leave for Breast Cancer Treatment Forced to Pay for... Fewer Women with Ovarian, Breast Cancer Undergo Genetic Testing than Expected
